Zoetis Inc. (ZTS) स्टॉक विश्लेषण

कंपनी का अवलोकन

Zoetis Inc. is a premier entity engaged in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, and precision animal health solutions for the United States and international markets. The corporation operates within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, positioning it as a key provider of specialized pharmaceutical interventions for animal health. This organization maintains a substantial operational scale with a market capitalization of $52.77B, an annual revenue of $9.47B, and a workforce comprising 14500 employees. These valuation and revenue figures indicate that the company commands a significant position within its niche, reflecting strong market confidence and a robust revenue generation capability that supports extensive research and commercialization activities globally.

वित्तीय स्वास्थ्य

The company reports a trailing twelve-month revenue of $9.47B and generates a net income of $2.67B, while reporting an EBITDA of $4.07B. The substantial gap between the $9.47B revenue and the $2.67B net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 71.8% of total revenue before arriving at the bottom line. Zoetis demonstrates strong financial flexibility with free cash flow of $1.79B, indicating the ability to fund operations, invest in R&D, or return capital without relying heavily on external financing. The firm exhibits robust profitability metrics across all three margin categories, with a gross margin of 71.9%, an operating margin of 34.7%, and a profit margin of 28.2%. The high gross margin reflects the premium nature of its specialty products, while the operating and profit margins suggest efficient management of overhead and effective cost control relative to sales. Regarding leverage, the company holds $2.31B in cash against $9.31B in debt, resulting in a debt-to-equity ratio of 279.59, which indicates a leveraged balance sheet where debt obligations significantly exceed equity capitalization. Despite the high debt level, the current ratio stands at 3.03, signaling strong short-term liquidity and an ample ability to cover current liabilities with available current assets. Return on equity is recorded at 66.0% and return on assets at 15.3%, metrics that reveal highly effective management in generating shareholder value and utilizing the company's asset base efficiently.

मूल्यांकन आकलन

Valuation metrics show a trailing P/E ratio of 19.89 and a forward P/E of 15.87. The difference between these two figures implies that the market expects earnings growth in the future, as the forward multiple is lower than the trailing multiple, suggesting the stock is priced with an expectation of increased profitability. The price-to-book ratio is 15.28, which indicates a significant market premium over the company's book value, reflecting intangible assets such as brand equity, intellectual property, and growth potential not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 5.57 and an EV/EBITDA of 14.15, suggesting that investors are willing to pay a premium for sales and earnings relative to peers in the specialty drug manufacturing space. The stock's recent price action ranges between a 52-week high of $172.23 and a 52-week low of $113.29. Without a specific current price provided in the facts, the valuation context relies on these range boundaries to understand historical volatility and trading levels over the past year. The beta value is 0.97, which means the stock's price volatility is nearly identical to that of the broader market, indicating it does not amplify or dampen market movements significantly.

Growth & Income

Zoetis reports a revenue growth of 3.0% year-over-year and an earnings growth of 6.1% year-over-year. The earnings growth rate of 6.1% is growing faster than the revenue growth rate of 3.0%, which implies operational leverage is being realized, allowing net income to expand at a quicker pace than top-line sales. As a dividend payer, the company offers a dividend yield of 1.8% with a payout ratio of 33.2%, indicating that the dividend is well-covered by earnings and is likely sustainable given the current profit margins. The moderate payout ratio suggests the company retains a significant portion of its earnings to fund internal growth initiatives rather than distributing all profits to shareholders. Overall, the growth and income profile presents a combination of steady, albeit modest, revenue expansion paired with accelerating earnings and a consistent, sustainable dividend stream for income-focused investors.